Education
About Us
Working with TipRanks
Follow Us
InflaRx NV (IFRX)
NASDAQ:IFRX
IFRX Stock Chart & Stats
$1.23
-$0.16(-6.27%)
At close: 4:00 PM EST
$1.23
-$0.16(-6.27%)
Day’s Range― - ―
52-Week Range$0.71 - $2.82
Previous CloseN/A
Volume66.97K
Average Volume (3M)574.11K
Market Cap
$85.26M
Enterprise Value-$2.12M
Total Cash (Recent Filing)$44.65M
Total Debt (Recent Filing)$970.86K
Price to Earnings (P/E)―
Beta0.50
Next Earnings
Mar 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding67,133,270
10 Day Avg. Volume649,163
30 Day Avg. Volume574,111
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)2.29
Price to Sales (P/S)847.69
P/FCF Ratio-2.89
Enterprise Value/Market Cap-0.02
Enterprise Value/Revenue-33.70
Enterprise Value/Gross Profit0.41
Enterprise Value/Ebitda0.05
Forecast
1Y Price Target
$4.00Price Target Upside225.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial StabilityInflarx has more than 1.5 years of cash available, indicating financial stability in the near term.
Market PotentialINF904's therapeutic signals indicate it could be a 'pipeline in a pill' with broad applicability in a wide range of indications and significant value generation potential for the company and stock.
Therapeutic DevelopmentsINF904 exhibits rapid and meaningful anti-inflammatory activity in both CSU and HS, especially vs. other therapeutics of the same class.
Bears Say
Efficacy ConcernsOverall, we don't think a clear efficacy signal jumps out as of now, and so we agree with the Company's plans to seek a partnership for this indication moving forward.
Industry ChallengesBiogen discontinued the development of its mAb against C5aR1, which could indicate challenges in this area that might also affect Inflarx.
Study LimitationsThe caveats are that this is a small study, there's no placebo arm, and targeting the C5a pathway has already failed in 2 placebo-controlled Phase 2 trials for HS.
InflaRx News
IFRX FAQ
What was InflaRx NV’s price range in the past 12 months?
InflaRx NV lowest stock price was $0.71 and its highest was $2.81 in the past 12 months.
What is InflaRx NV’s market cap?
InflaRx NV’s market cap is $85.26M.
When is InflaRx NV’s upcoming earnings report date?
InflaRx NV’s upcoming earnings report date is Mar 19, 2026 which is in 125 days.
How were InflaRx NV’s earnings last quarter?
InflaRx NV released its earnings results on Oct 30, 2025. The company reported -$0.212 earnings per share for the quarter, beating the consensus estimate of -$0.213 by <$0.001.
Is InflaRx NV overvalued?
According to Wall Street analysts InflaRx NV’s price is currently Undervalued.
Does InflaRx NV pay dividends?
InflaRx NV does not currently pay dividends.
What is InflaRx NV’s EPS estimate?
InflaRx NV’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InflaRx NV have?
InflaRx NV has 67,133,270 shares outstanding.
What happened to InflaRx NV’s price movement after its last earnings report?
InflaRx NV reported an EPS of -$0.212 in its last earnings report, beating expectations of -$0.213. Following the earnings report the stock price went down -4.348%.
Which hedge fund is a major shareholder of InflaRx NV?
Currently, no hedge funds are holding shares in IFRX
InflaRx Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (225.20% Upside)
$4.00 (225.20% Upside)
Hedge Fund Trend
Increased
By 2.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 61.5%
Last 30 Days ▲ 71.7%
Last 30 Days ▲ 71.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.87%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-13.54%
Trailing 12-Months
Company Description
InflaRx NV
InflaRx (IFRX) is a biopharmaceutical company focused on developing innovative therapies for inflammatory diseases. The company specializes in monoclonal antibodies targeting the complement system, which plays a critical role in immune response and inflammation. InflaRx's lead product candidate, IFX-1, is designed to treat conditions such as hidradenitis suppurativa and other severe inflammatory diseases, positioning the company at the intersection of immunology and biotherapeutics.
IFRX Stock 12 Month Forecast
Average Price Target
$4.00
▲(225.20% Upside)
Technical Analysis
Oramed Pharm
―
Atara Biotherapeutics
―
Anixa Biosciences
―
Clene
―
Acumen Pharmaceuticals
―
Ownership Overview
―
Insiders
0.07% Mutual Funds
0.13% Other Institutional Investors
99.80% Public Companies and
Individual Investors